| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/15/2003 | EP1274862A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 01/15/2003 | EP1274852A2 Targeted vaccine delivery systems |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274844A2 G-protein coupled receptors and nucleic acids encoding same |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274711A1 New aza-indolyl derivatives |
| 01/15/2003 | EP1274710A2 Novel heteroaryl-diazabicycloalkanes |
| 01/15/2003 | EP1274709A1 Salts of bicyclic, n-acylated imidazo-3-amines and imidazo-5-amines |
| 01/15/2003 | EP1274701A1 Chemical compounds |
| 01/15/2003 | EP1274698A1 Percyquinnin, a process for its production and its use as a pharmaceutical |
| 01/15/2003 | EP1274697A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 01/15/2003 | EP1274694A1 Novel compounds |
| 01/15/2003 | EP1274692A1 Quinazoline compounds |
| 01/15/2003 | EP1274691A1 2-guanidino-4-arylchinazolines as nhe-3 inhibitors |
| 01/15/2003 | EP1274687A1 1,2,3,4- tetrahydroisoquinoline derivatives |
| 01/15/2003 | EP1274675A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 01/15/2003 | EP1274464A2 Compositions and methods for regulated protein expression in gut |
| 01/15/2003 | EP1274452A1 Method of preventing or treating diabetes |
| 01/15/2003 | EP1274450A2 Cytokine uses; compositions; methods |
| 01/15/2003 | EP1274449A2 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| 01/15/2003 | EP1274429A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 01/15/2003 | EP1274424A1 Compounds and methods |
| 01/15/2003 | EP1274418A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage |
| 01/15/2003 | EP1274412A1 Pharmaceutical formulation |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 01/15/2003 | EP1274322A1 Composition comprising free amino acids |
| 01/15/2003 | EP1274319A2 Compositions and methods for improving vascular health |
| 01/15/2003 | EP1235488A4 Product and method for control of obesity |
| 01/15/2003 | EP1169317B1 Triarylimidazoles |
| 01/15/2003 | EP1112064B1 Method for preparing novel fenofibrate galenic formulations, galenic formulations obtained and applications |
| 01/15/2003 | EP0820451B1 Novel heterocyclic compounds |
| 01/15/2003 | EP0778767B1 Delivery of solid drug compositions |
| 01/15/2003 | EP0713483B1 Amidine derivatives with nitric oxide synthetase activities |
| 01/15/2003 | EP0584347B1 Enantiomeric hydroxylated xanthine compounds |
| 01/15/2003 | CN1391605A Gynogenetic or androgenetic production of pluripotent cells and cell lines, and use thereof to produce differentiated cells and tissues |
| 01/15/2003 | CN1391571A Heterocyclic compounds and their use as medicines |
| 01/15/2003 | CN1391570A Phenyl-and pyridyl-tetrahydro-pyridines having TNF inhibiting activity |
| 01/15/2003 | CN1391558A Substituted 1,3-diaryl-2-pyridine-2-yl-3-(pyridine-2-ylamino)-propanol derivatives, methods for their production, pharmaceutical compositions containing the same and their use |
| 01/15/2003 | CN1391479A Medicament for inducing tolerance |
| 01/15/2003 | CN1391477A Physical strength enhancing agents and glycogen accumulation promoting agents |
| 01/15/2003 | CN1391474A 5-membered heterocycle derivatives, production thereof and use as medicaments |
| 01/15/2003 | CN1391473A VLA-4 inhibitor compounds |
| 01/15/2003 | CN1391469A Npyy5拮抗剂 Npyy5 antagonist |
| 01/15/2003 | CN1391467A Method of microencapsulation |
| 01/15/2003 | CN1390594A Mixture for improving blood circulation |
| 01/15/2003 | CN1390577A Pill of tortoise plastron and turtle shell |
| 01/15/2003 | CN1390552A Health-care mineral food and its preparing process |
| 01/15/2003 | CN1390499A Hypolipemic health-care beverage and its preparing process |
| 01/15/2003 | CN1098858C Momordicine extracting process |
| 01/15/2003 | CN1098841C Novel amide derivatives and medicinal compositions thereof |
| 01/15/2003 | CN1098684C Orally administerable pharmaceutical formulations |
| 01/15/2003 | CN1098679C Methods and compositions for pulmonary delivery of insulin |
| 01/15/2003 | CN1098643C Chewing gum for supplementing calcium and taking tooth care |
| 01/14/2003 | US6506912 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 01/14/2003 | US6506911 Pyrano [3,2-d]-1,3-dioxin-8 ones |
| 01/14/2003 | US6506891 Cell surface molecule-induced macrophage activation |
| 01/14/2003 | US6506874 Hypoglycemic agents; obesity, nervous system, cardiovascular, and kidney disorder treatment |
| 01/14/2003 | US6506802 Disulfide derivatives useful for treating allergic diseases |
| 01/14/2003 | US6506799 Treating or preventing a cardiovascular disease in a patient, comprising administering to a patient in need of such treatment or prevention a therapeutically effective amount of 6-(6-hydroxy-5,5-dimethylhexyloxy)-2,2-dimethyl-hexan-1-ol and |
| 01/14/2003 | US6506797 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) α |
| 01/14/2003 | US6506796 Cosmetically or therapeutically treating diseases or disorders in cell populations whose pathology is linked to an inadequate rate of apoptosis by administering a therapeutically effective amount of |
| 01/14/2003 | US6506781 Prevent formation of a hydrogen bond between the agonist and tyrosine or histidine, or tryptophan involved in receptor activation; and/or b) displace the tyrosine or histidine, or tryptophan involved in receptor activation from its agonist |
| 01/14/2003 | US6506779 Acetylene derivatives as anti-inflammatory/analgesic agents |
| 01/14/2003 | US6506778 Acylphenylurea derivatives, a process for their preparation and their use as pharmaceuticals |
| 01/14/2003 | US6506768 Tetrahydro γ-carbolines |
| 01/14/2003 | US6506762 Certain alkylene diamine-substituted heterocycles |
| 01/14/2003 | US6506756 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists |
| 01/14/2003 | US6506748 Aromatic heterocyclic compounds as antiinflammatory agents |
| 01/14/2003 | US6506740 Compounds that can be substituted at the 7, 8, and/or 9 positions and methods for preparing the 4- dedimethylamino tetracycline compounds. Other tetracycline compounds are the 4-dedimethylaminotetracycline derivatives with an oxime |
| 01/14/2003 | US6506724 Exendins are peptides that were first isolated from the salivary secretions of the Gila-monster, a lizard found in Arizona and have some sequence similarity to several members of the glucagon-like peptide |
| 01/14/2003 | US6506555 Use of HIV protease inhibiting compounds |
| 01/14/2003 | US6506383 Methods of suppressing immune responses to transplanted tissues and organs with gp39-specific antibodies |
| 01/14/2003 | CA2056322C Ginkgo biloba acting as alpha-2-blocker slimming compound |
| 01/09/2003 | WO2003002596A2 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| 01/09/2003 | WO2003002595A2 Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/09/2003 | WO2003002593A2 Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| 01/09/2003 | WO2003002586A1 [4-(4-cyanobenzoyl)phenyl]glycofuranoside derivatives, use of said derivatives as a medicament, production method thereof and pharmaceutical compositions containing same |
| 01/09/2003 | WO2003002575A1 3-ARYL-$G(a)-OXY SUBSTITUTED PROPANOIC ACIDS AND A PROCESS FOR THEIR PREPARATION |
| 01/09/2003 | WO2003002571A1 Aryl boronate functionalized polymers for treating obesity |
| 01/09/2003 | WO2003002570A1 Aryl boronic acids for treating obesity |
| 01/09/2003 | WO2003002569A1 Method of inhibiting ptp 1b and/or t-cell ptp and/or other ptpases with an asp residue at position 48 |
| 01/09/2003 | WO2003002561A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | WO2003002559A2 Piperidine compounds for use as orexin receptor antagonist |
| 01/09/2003 | WO2003002555A1 Methods of using soluble epoxide hydrolase inhibitors |
| 01/09/2003 | WO2003002553A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002544A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | WO2003002533A1 Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| 01/09/2003 | WO2003002531A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002530A2 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | WO2003002508A1 Derivatives of para-ethoxy-phenillactic acid |
| 01/09/2003 | WO2003002149A2 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food |
| 01/09/2003 | WO2003002147A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 01/09/2003 | WO2003002145A1 Diagnosis and treatment of insulin-dependent diabetes mellitus and insulitis |
| 01/09/2003 | WO2003002140A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 01/09/2003 | WO2003002137A2 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/09/2003 | WO2003002136A2 Stable formulation of modified glp-1 |
| 01/09/2003 | WO2003002130A1 Fat-binding polymers |
| 01/09/2003 | WO2003002127A1 Use of at least one glycoinhibitor substance |